Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

出版年份 2018 全文链接

标题

作者

关键词

出版物

Volume 19, Issue 4, Pages 521-536

出版商

Elsevier BV

发表日期

2018-03-13

DOI

10.1016/s1470-2045(18)30144-x

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started